Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937531 | 0.86 | PER2 (0.43) | PER2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30937569 | 0.86 | BRD4 (0.51) | PER2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30937552 | 0.85 | PLA2G10 (0.38) | PER2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30937599 | 0.83 | DRD2 (0.39) | PDE4APDE4BPDE4CPDE4DBRD4 | |
| SCHEMBL30937748 | 0.81 | ALDH1A1 (0.43) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL30937538 | 0.81 | PER2 (0.45) | PER2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30937533 | 0.80 | PLA2G10 (0.36) | PER2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17796131 | 0.78 | GPR119 (0.46) | KDM4EMAPT | |
| SCHEMBL31120568 | 0.77 | ACE (0.40) | OPRM1OPRL1MAPK1PLA2G10PLA2G5 | |
| SCHEMBL30937762 | 0.77 | ACE (0.40) | OPRM1OPRL1MAPK1PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2024073426-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | PER2 4156/4885PDE4A 1521/4885PDE4B 1372/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | PER2 3698/4885PDE4A 191/4885PDE4B 332/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | PER2 3698/4885PDE4A 191/4885PDE4B 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.